Teneligliptin improves glycemic control with the reduction of postprandial insulin requirement in Japanese diabetic patients

Tsuchimochi, Wakaba; Ueno, Hiroaki; Yamashita, Eiichiro; Tsubouchi, Chikako; Sakoda, Hideyuki; Nakamura, Shuji; Nakazato, Masamitsu

doi:10.1507/endocrj.ej14-0393

Cited by 25 publications

(16 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The incidence of Gastro-intestinal adverse events was more in metformin group than teneligliptin Wakaba T et al study was to evaluate the effects of teneligliptin on 24 hour blood glucose control and gastrointestinal hormone responses to a meal tolerance test, and to investigate the glucose-lowering mechanisms of teneligliptin. 8 Teneliglipt in was given once a day for 3 days significantly lowered fasting and postprandial glucose levels. Significant elevations of fasting and postprandial active GLP-1 and postprandial active GIP levels were observed.…”

Section: Discussionmentioning

confidence: 96%

Efficacy of teneligliptin in type 2 diabetes mellitus

Riyaz

Ahmed²,

Banu³

2016

Int J Res Med Sci

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 96%

Efficacy of teneligliptin in type 2 diabetes mellitus

Riyaz

Ahmed²,

Banu³

2016

Int J Res Med Sci

View full text Add to dashboard Cite

“…Study showing the beneficial effects of teneligliptin on insulin sensitivity was not with monotherapy. 17,18 In these papers, the insulin-sensitizing properties of teneligliptin were evaluated as add-on to other diabetes e.g. metformin).…”

Section: Insulin Sensitizing Properties Of Vildagliptin and Teneliglimentioning

confidence: 99%

Comparative effect of vildagliptin and teneligliptin on HbA1c, glycemic efficacy and insulin sensitivity

Chudiwal¹

2017

Int J Basic Clin Pharmacol

View full text Add to dashboard Cite

Background: Vildagliptin, a potent and selective dipeptidyl peptidase-4 (DPP-4) inhibitor, increases the availability of endogenous incretin hormones, glucagon-like peptide (GLP-1), and glucose-dependent insulinotropic polypeptide, thereby improving glycemic control. The objective of this study is to further investigate the insulin sensitizing properties of Vildagliptin in comparison to those of Teneligliptin.Methods: Naive subjects with T2DM were administered 50-100mg/day Vildagliptin monotherapy (n = 53). As a comparator, monotherapy, 20mg/day Teneligliptin monotherapy was performed in a non-randomized manner (n=58). No other drugs were administered. At 3 month, levels of diabetic parameters were compared with those at baseline.Results: At 3 months, while similar reductions of glycated hemoglobin (HbA1c) levels were observed with these two drugs, indexes for insulin sensitivity homeostasis model assessment (HOMA)-R ameliorated only with Vildagliptin. Then, the subjects were divided into two groups representing distinct degrees of insulin resistance; high HOMA-R (C4) and low HOMA-R (2) groups. With Vildagliptin, similar decreases of HbA1c levels were observed in high (10.85-8.66%, p\0.0005) and low (11.12-8.91%, p\0.01) HOMA-R groups. HOMA-R (-31.9%, p\0.05) and non-high density lipoprotein cholesterol (non-HDL-C, -7%, p\0.05) levels significantly decreased. HOMA-B levels increased in both groups with significant inter-group differences (102.1 % in low HOMA-R group vs. 53.4 % in high HOMA-R group). Group 2. With Teneligliptin similar decreases of HbA1c levels were observed from those of vildagliptin in either high or low HOMA-R group, but no changes of HOMA-R, non-HDL-C levels were noted. Increases of HOMA-B levels with teneligliptin were comparable to those with vildagliptin in either high or low HOMA-R group.Conclusions: These results indicate that vildagliptin ameliorates insulin sensitivity and non-HDL-C levels in subjects with high degrees of insulin resistance and vildagliptin also shows glycemic efficacy by decreasing HbA1c. This is not the case with teneligliptin though similar glycemic efficacies were observed.

show abstract

“…Wakaba Tsuchimochi et al [50] showed that once daily Teneligliptin administration for 3 days significantly lowered postprandial and fasting glucose levels. Significant elevations of fasting and postprandial active GLP-1 and postprandial active GIP levels were observed.…”

Section: Clinical Journey Of Teneligliptinmentioning

confidence: 99%